Directed γ-C(sp<sup>3</sup>)–H Alkylation of Carboxylic Acid Derivatives through Visible Light Photoredox Catalysis
作者:Dian-Feng Chen、John C. K. Chu、Tomislav Rovis
DOI:10.1021/jacs.7b09306
日期:2017.10.25
Visible light photoredox catalysis enables direct γ- C(sp3)-H alkylation of saturated aliphatic carbonyl compounds. Electron-deficient alkenes are used as the coupling partners in this reaction. Distinguished site selectivity is controlled by the predominant 1,5-hydrogen atom transfer of an amidyl radical generated in situ.
Cyclopentenones are synthetically versatile structures, and their straightforward construction from alkynone substrates by employing synthetically streamlining C-H insertion is conceptually appealing and of high synthetic potential. But, its implementation is very limited. Herein we report a Au-catalyzed version, which affords 2-bromocyclopent-2-en-1-ones with a broad scope and synthetically desirable
环戊烯酮是合成通用的结构,它们通过合成流线型 CH 插入从炔酮底物直接构建在概念上具有吸引力且具有高合成潜力。但是,它的实施非常有限。在此我们报告了一种 Au 催化的版本,它提供了具有广泛范围和合成所需的非对映选择性的 2-bromocyclopent-2-en-1-ones。所提出的能够插入未活化 CH 键的关键中间体是一种完全功能化的金亚乙烯基,它是通过一种新的分子间策略产生的。这种可能的金亚乙烯基的灵活获取为探索其多功能反应性提供了各种机会。
Cannabinoid receptor ligands and uses thereof
申请人:Pfizer Inc.
公开号:US20040077650A1
公开(公告)日:2004-04-22
Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the modulation of the cannabinoid receptors in animals are described herein.
1
本文描述了作为大麻素受体配体的化合物(I)及其在治疗与动物体内大麻素受体调节相关疾病中的用途。
Vinylogous acid derivatives
申请人:Banner David
公开号:US20080096953A1
公开(公告)日:2008-04-24
The invention is concerned with novel vinylogous acid derivatives of formula I:
wherein A and R
1
to R
5
are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are useful as chymase inhibitors.
ALPHA-AMINO ACID DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME AS AN ACTIVE INGREDIENT
申请人:Ohrai Kazuhiko
公开号:US20090275623A1
公开(公告)日:2009-11-05
The present invention provides novel α-amino acid derivatives of formula (1):
(wherein, R
1
, R
2
, R
3
, R
4
, X and Y are as defined in the claims) or pharmaceutically acceptable salts, prodrugs or solvates thereof. The derivatives of formula (1) have βARK1 inhibitory activity and are useful for preventing or treating heart failure. Moreover, the derivatives of formula (1) also have antitumor activity, particularly dual inhibitory activity on Aurora kinase and CDK, and are useful for cell proliferative diseases such as cancer.